Fibrocystic mastopathy: signs and treatment

Fibrocystic breast disease is a benign tissue change characterized by dense areas of fibrosis and cysts, leading to engorgement, tenderness, and lumpiness, especially around menstruation. This is an extremely common condition, not cancerous, and typically does not increase the risk of cancer in simple cases. [1]

In modern terminology, the neutral terms "fibrocystic changes" or "fibrocystic remodeling" are used, emphasizing the variability of manifestations and the lack of need to "treat" findings in the absence of pronounced symptoms. Most often, observation, lifestyle modification, and topical pain relief are sufficient. [2]

Symptoms range from moderate discomfort to severe mastalgia with cyclical fluctuations. Women often report increased sensitivity and swelling 3-7 days before menstruation, with relief following its onset. With careful management and proper information, overdiagnosis and unnecessary invasive procedures can be avoided. [3]

It's important to distinguish benign changes from situations that require targeted imaging: the appearance of a palpable lesion, skin or nipple retraction, bloody discharge, "orange peel" appearance, or persistent inflammation. These signs warrant expedited referral to a mammologist for instrumental evaluation. [4]

Code according to ICD-10 and ICD-11

In the International Classification of Diseases, Tenth Revision, fibrocystic changes are included in the category N60 "Benign Dysplasia of the Breast." For diffuse cystic mastopathy, codes N60.1 are used (with specification by side: N60.11, N60.12, N60.19), for fibroadenosis - N60.2, for fibrosclerosis - N60.3, etc. The choice of code depends on the clinical picture and imaging results. [5]

In the International Classification of Diseases, Eleventh Revision, the corresponding heading is GB20 "Benign Diseases of the Breast," where the code GB20.0 "Fibrocystic Change of Breast" is provided for fibrocystic changes. If necessary, more general positions of the group GB20.Y "Other Specified Benign Diseases of the Breast" are used. [6]

Table 1. Corresponding ICD codes

Classification	Code	Name	Note
ICD-10	N60	Benign mammary dysplasia	Superheading for fibrocystic changes
ICD-10	N60.1 (N60.11/12/19)	Diffuse cystic mastopathy	With clarification from the party
ICD-10	N60.2 (N60.29)	Fibroadenosis	Various subtypes
ICD-10	N60.3	Fibrosclerosis of the mammary gland	Fibrous component
ICD-11	GB20.0	Fibrocystic breast changes	Basic ICD-11 code
ICD-11	GB20.Y	Other specified benign diseases	Used for other clarifications
Source: official reference books ICD-10/ICD-11. [7]

Epidemiology

This is the most common benign breast pathology in women of reproductive age: according to various estimates, signs of fibrocystic remodeling are observed in more than 50-70 percent of women during their lifetime, most often between the ages of 30 and 50. After menopause, the severity of symptoms decreases, with the exception of women on hormone replacement therapy. [8]

No association with an increased risk of breast cancer has been identified in simple forms (fibrosis and simple cysts). Risk may vary in proliferative histological variants with atypia, but these are no longer "simple" fibrocystic changes, but a different group of benign diseases with a different behavior and follow-up. [9]

Most visits to breast clinics are related to pain and lumps, but with proper triage, a significant proportion of patients are treated in primary care without urgent imaging. This reduces the burden on specialized services without compromising safety. [10]

The prevalence of symptomatic mastalgia among women with fibrocystic changes is estimated at 20-30 percent, with pain severity varying depending on the phase of the menstrual cycle and associated factors such as stress, strain, and breast support.[11]

Reasons

Hormonal fluctuations in estrogen and progesterone during the luteal phase play a key role, altering the water balance and receptor sensitivity in breast tissue. This leads to stromal edema, stretching of receptor fields, and the appearance of pain and swelling. [12]

Individual tissue sensitivity to hormones and inflammatory mediators, including prostaglandins, contributes. Against this background, any additional triggers (stress, overexertion, tight underwear) more easily provoke symptoms. [13]

Medications (combined hormonal contraceptives, hormone replacement therapy, etc.) may exacerbate symptoms. In some patients, symptoms are alleviated by adjusting or changing medications after discussion with a physician. [14]

Fibrosis and cyst formation are the result of multiple cyclical processes: microinflammation, fluid retention, proliferative processes, and reverse regression. Over time, some lesions "settle" as benign cysts or dense areas without progression. [15]

Risk factors

The most common factors are premenopausal age, premenstrual syndrome, high breast density, weight fluctuations, stress, and inadequate breast support in daily life and sports. The individual impact of caffeine is debated, but the evidence base is mixed. [16]

In women on hormone replacement therapy, symptoms may persist after menopause; however, the decision to continue therapy is individualized based on benefit and discomfort. [17]

A family history of breast cancer does not in itself predict fibrocystic changes, but it is important for screening and assessing overall cancer risk. The presence of proliferative benign changes with atypia in the family history is considered a different risk category and is managed according to separate protocols. [18]

Physical factors - overload of the chest wall, poor posture and ill-fitting bras - often maintain the pain syndrome, disguising it as “pain in the gland”, although the source is in the muscular-fascial structures of the chest. [19]

Table 2. Main factors associated with symptoms

Category	Examples	Practical significance
Hormonal	Cycle phase, pregnancy, hormone replacement therapy	Determine the cyclical nature of pain
Fabric	Dense glandular tissue, cysts, fibrosis	Create foci of sensitivity
Medicinal	Contraceptives, hormone replacement therapy	Correction of therapy is possible
Biomechanical	Posture, load, chest support	Often a "mask" of chest wall pain
Behavioral	Stress, caffeine (debatable)	Individual triggers
Source: clinical reviews and educational materials from leading organizations. [20]

Pathogenesis

Cyclical hormonal fluctuations cause stromal swelling and ductal dilation, which mechanically irritates receptors and creates a pain pattern. This explains the intensification of symptoms in the second phase of the cycle and their weakening at the onset of menstruation. [21]

Repeated “microwaves” of edema and regression promote tissue remodeling: areas of fibrosis appear and cysts of various sizes are formed, most often simple, thin-walled and benign according to visual signs. [22]

The pain component is modulated by prostaglandins and peripheral sensitization. Therefore, topical nonsteroidal anti-inflammatory drugs that inhibit prostaglandin synthesis demonstrate clinical benefit with a good safety profile. [23]

In the presence of proliferative benign processes with atypia (this is a different category), the prognosis and observation tactics change - such a case goes beyond the scope of “simple” fibrocystic changes and requires oncology-risk-oriented management. [24]

Symptoms

The most typical symptoms are engorgement, "lumpiness," and soreness, which intensify before menstruation and subside after it begins. The pain is often bilateral and diffuse, and may radiate to the axillary region. [25]

Palpation reveals soft, elastic, mobile, painful areas or cysts; their benign nature is confirmed by puncture or dynamic observation. It is vital to distinguish such findings from a hard, "stony," painless lesion that is growing in size. [26]

Some women experience clear or milky-white discharge from the nipple without a bloody component; in case of unilateral bloody discharge from one duct, the tactics change - in-depth diagnostics are required. [27]

Psychoemotional anxiety due to "cancer fear" itself increases pain perception. Explaining the low oncological significance of simple fibrocystic changes and a clear monitoring plan reduce distress and the frequency of unnecessary examinations. [28]

Table 3. Red flags requiring accelerated visualization

Sign	Why is it important?	The next step
Palpable hard nodule	Tumor risk	Age-appropriate mammography + targeted ultrasound examination
Retraction of the skin or nipple	Possible oncological process	Urgent consultation with a mammologist
Unilateral bloody discharge	Probable intraductal lesions	Multifactorial imaging, sometimes ductography
"Orange peel"	Inflammatory cancer?	Immediate assessment
Persistent inflammation/fever	Abscess, rare tumors	Ultrasound examination and treatment as indicated
Source: ACR Appropriateness Criteria, positions of professional associations. [29]

Classification, forms and stages

Clinically, a distinction is made between "simple" fibrocystic changes (fibrosis and simple cysts) and proliferative benign diseases (e.g., sclerosing adenosis, atypical hyperplasia), which are beyond the scope of this topic and require a different risk assessment. This is important for the selection of observations. [30]

Symptoms are divided into asymptomatic and symptomatic forms; the latter are accompanied by mastalgia and increased sensitivity. Symptoms are not identical to oncological risk, but rather reflect the tissue's pain sensitivity and the influence of triggers. [31]

Depending on localization, changes can be diffuse or focal. Focal cysts and dense areas require targeted ultrasound verification; diffuse changes with typical clinical features are often managed conservatively. [32]

Pain diaries and visual analogue scales are useful for monitoring symptom severity; this helps personalise treatment and objectively assess the effect of interventions. [33]

Complications and consequences

Simple fibrocystic changes do not increase the risk of breast cancer and usually do not lead to structural complications. The main negative effect is a decrease in quality of life due to pain and anxiety. [34]

Cysts may recur and cause discomfort; for large, tense cysts, therapeutic needle aspiration with follow-up may be performed. This is a minimally invasive and effective procedure when indicated. [35]

Excessive and untimely imaging increases the rate of false-positive findings, repeat visits, and biopsies without affecting outcomes, as emphasized by guidelines. It is important to adhere to evidence-based algorithms. [36]

In proliferative benign processes with atypia (a separate group), the prognosis and risk-oriented tactics are different; such cases are managed according to special monitoring and prevention protocols. [37]

When to see a doctor

A visit to the doctor is recommended if pain persists for more than 2-4 weeks, a palpable lesion appears, unilateral bloody discharge, skin or nipple retraction, or signs of inflammation with fever. Don't wait if any of the "red flags" are present. [38]

Even with typical cyclical pain, it is important to follow age-specific breast cancer screening guidelines. Screening is scheduled and is not dependent on the presence or absence of symptoms of fibrocystic changes. [39]

During pregnancy and lactation, ultrasound examination is the safest method for assessing foci and pain; the tactics of invasive procedures and radiation methods are discussed individually, taking into account the indications. [40]

If the pain resembles musculoskeletal pain (increases with movement, palpation of the costal joints, and load), this is a strong argument in favor of a source in the chest wall - in this case, the strategy is adjusted. [41]

Diagnostics

The first step is a medical history and physical examination: the nature of the pain (cyclicity, location), its relationship to the cycle, medications and hormonal factors, the presence of discharge, nodules, and skin changes. Palpation of the entire breast and regional areas is performed, and the chest wall is assessed for trigger points. [42]

In the case of a typical presentation without any "red flags," unscheduled imaging is not required; observation and symptomatic care are sufficient. In the case of focal complaints or warning signs, imaging is age-appropriate: in young patients, ultrasound is started; after age 40, mammography is added. [43]

Ultrasound examination allows for the verification of simple cysts (anechoic, thin-walled, with distal enhancement) and the differentiation from complex or solid lesions. Mammography is more informative in the age group over 40 years and for the evaluation of calcifications. [44]

Invasive methods (fine-needle aspiration, core biopsy) are used according to indications: tense symptomatic cyst, suspicious findings on imaging, discrepancy between clinical presentation and imaging. Routine blood tests are not necessary for a typical presentation. [45]

Table 4. Visualization tactics for suspected fibrocystic changes

Clinical situation	Age	Recommended steps
Diffuse cyclic pain, examination without pathology	Any	No unscheduled imaging; observation and symptomatic care
Focal complaints, examination without pathology	< 40	Ultrasound as the 1st test
Focal complaints or "red flags"	≥ 40	Mammography + targeted ultrasound examination
Suspicious find	Any	Biopsy according to indications (core biopsy/aspiration)
Source: ACR Appropriateness Criteria and review publications. [46]

Table 5. Step-by-step algorithm for management in primary care

Step	Action	Target
1	Anamnesis, examination, pain diary	Classify the symptom, identify red flags
2	Visualization decision according to table 4	Exclude significant pathology
3	Patient education and non-drug care plan	Reducing pain and anxiety
4	Local tools, brief system tools if necessary	Symptom control
5	Control after 4-8 weeks	Assess the effect and adjust tactics
Source: ABS positions and regional routes for chest pain.[47]

Differential diagnosis

It is important to distinguish simple cysts and fibrosis from solid benign nodules (e.g., fibroadenoma) and malignant tumors. Fibroadenoma is characterized by a painless, smooth, mobile nodule in young patients; if in doubt, ultrasound verification and, if indicated, biopsy are performed. [48]

Inflammatory conditions (mastitis, abscesses) are considered separately; they are accompanied by redness, localized pain, and sometimes fever. Ultrasound and prompt antibiotic therapy or drainage are helpful here. [49]

Chest wall pain (costochondritis, myofascial syndromes) is often disguised as "chest pain," but is reproduced by palpation of the costochondral joints and muscles. If the glandular parenchyma is normal according to ultrasound, emphasis is placed on non-drug treatments and topical nonsteroidal anti-inflammatory drugs. [50]

Finally, any new “lump” in a woman over 40 years of age requires a structured approach to the palpable formation (using algorithms) in order to exclude cancer and at the same time avoid excessive procedures in benign cases. [51]

Treatment

The basis is patient education and simple non-pharmacological measures: a supportive bra of the correct size, posture and exercise correction, heat or cold applications as tolerated, and limiting individual triggers. For most, this is a sufficient first-line strategy. [52]

Topical nonsteroidal anti-inflammatory drugs (eg, diclofenac gels) reduce pain in cyclic and noncyclic mastalgia, with a favorable safety profile due to minimal systemic exposure. They are considered the preferred initial pharmacotherapy. [53]

Oral analgesics (ibuprofen, paracetamol) are used in short courses when pain intensifies. They are effective, but due to systemic effects and gastrointestinal and renal risks, they are best used "as needed, but as briefly as possible," with priority given to localized forms. [54]

Evening primrose oil and vitamin E supplements are frequently discussed by patients. Large reviews indicate mixed evidence: overall, efficacy is comparable to placebo or no superior to topical nonsteroidal anti-inflammatory drugs and danazol; however, the safety profile is acceptable. The decision is individualized, with the effect assessed after 8-12 weeks. [55]

For severe, recalcitrant mastalgia, a short course of tamoxifen at a low dose of 10 mg may be considered, having shown comparable pain relief with fewer side effects compared to 20 mg in early randomized trials and subsequent reviews. This is used after the failure of basic measures, under observation. [56]

When prescribing tamoxifen, the risks of venous thrombosis, endometrial changes, and vasomotor symptoms are taken into account; the course is kept to a minimum. Low-dose regimens in cancer prevention studies have further supported the idea of "less is safer" while maintaining the target effect. [57]

Danazol can reduce pain, but is limited by androgenic side effects (acne, weight gain, voice changes). Therefore, today it is reserved for selected cases and after informed consent, when other approaches have failed or are contraindicated. [58]

Broad-spectrum hormonal interventions (gonadotropin-releasing hormone agonists, etc.) for mastalgia and fibrocystic changes are used extremely rarely due to the benefit-risk ratio; in routine practice, they are avoided, preferring local and minimally systemic methods. [59]

For large, tense cysts with significant discomfort, a thin-needle aspiration under ultrasound guidance is performed for diagnostic and therapeutic purposes. If the cyst is simple and completely resolves without any suspicious symptoms, observation is sufficient; if it relapses, the treatment plan is discussed again. [60]

The key to success is a monitoring plan: follow-up visits every 4-8 weeks, a pain diary, adjustments to underwear and exercise, and reassessment of the need for pharmacotherapy. If any "red flags" appear, the patient is immediately referred for a more in-depth diagnostic evaluation. This approach reduces anxiety and prevents iatrogenic cascades. [61]

Table 6. Comparison of treatment options

Approach	Efficiency	Side effects	When to choose
Education, breast support, heat/cold	Moderate, frequent sufficiency	Minimum	First line to everyone
Local nonsteroidal anti-inflammatory drugs	Good for pain	Local light	Often as a starting medication
Oral analgesics (briefly)	Moderate	Systemic	In case of exacerbations, short courses
Evening Primrose Oil/Vitamin E	Unstable evidence	Generally well tolerated	Upon request, with re-evaluation in 8-12 weeks
Tamoxifen 10 mg (short course)	High in resistant pain	Thrombosis, endometrium, vasomotor	The second line of the selected
Danazol	There is an effect.	Androgenic	Reserve in case of failure of other measures
Source: randomized trials and reviews. [62]

Prevention

Choosing the right bra, especially during active wear, reduces mechanical stress on ligaments and fascia and lowers the risk of pain. Correct posture, ergonomics at the workplace, and a gradual increase in exercise are also important. [63]

Individualized interventions with triggers (stress management, diet, sleep patterns) help control subjective pain sensitivity. Evidence on the effects of caffeine is mixed, so recommendations are personalized based on actual response. [64]

A rational approach to hormonal therapy (selection of doses, forms, and regimens) reduces fluctuations in symptoms; any changes are discussed with a doctor, assessing the balance of benefits and discomfort. [65]

Compliance with age-related mammography screening programs remains the basis of cancer prevention and does not depend on the presence of fibrocystic changes. [66]

Table 7. Practical steps for self-help

Step	What to do	How to understand what helps
Breast support	A bra that fits, especially when active	Less nagging pain in the evening
Load correction	Gradualism, warm-up, work on posture	Less chest wall pain
Thermal therapy	Heat/cold locally as tolerated	Rapid symptom relief
Pain Diary	Track cycles and triggers	Personalization of tactics
Source: recommendations of professional communities. [67]

Forecast

The prognosis is favorable: many women experience symptom improvement over time, especially after menopause without hormone replacement therapy. Most respond to a combination of non-drug measures and topical medications. [68]

Simple fibrocystic changes do not increase the risk of cancer. The exception is certain proliferative benign conditions with atypia, which are managed according to different protocols. Clear classification during the initial evaluation is the basis for safe management. [69]

Overdiagnosis without indications does not improve outcomes and increases the number of false positive findings; adhering to ACR algorithms and national pathways ensures both safety and prudent use of resources. [70]

The follow-up plan is simple: information, symptom monitoring after 4-8 weeks, adjustments as needed, and prompt referral if any red flags appear. This approach reduces anxiety and increases treatment satisfaction. [71]